CAGR: 25.18% Current Market Size: USD 694.92 millionFastest Growing Region: APAC
Largest Market: North AmericaProjection Time: 2022-2028Base Year: 2020
Global automated and closed-cell therapy processing systems market is expected to reach USD 5431.06 million by 2028, at a CAGR of 25.18% from 2022 to 2028. This growth of the automated and closed-cell therapy processing systems market is significantly driven by the rising demand for specific regeneration medicines. Automation technology offers several benefits through which these systems can be developed. The increasing requirement of automation in closed-cell therapy processing is fueling the growth of the market.
The commercialization of cell therapy requires the passing of stringent regulations at every stage. Cell therapy provides a way for the finding of various new regenerative medicines. The antibodies are manufactured using cell therapy processing systems. The manufacturing of cell and genes therapy is complex and thus requires intensive labor during the whole process. The processing of cells and genes requires various procedures and steps, including separation, expansion, apheresis, fill-finish, and preservation. Thus, in order to develop a successful cell therapy procedure, the use of automated systems is required. The use of automated and closed-cell therapy processing systems helps in conducting the cell therapy process safely and simply.
The automated and closed-cell therapy processing system are majorly used in commercial and clinical cell processing operations. The closed-cell therapy processing systems offer the highest protection against contamination. The presence of contamination can influence the test result, hence affecting the efficacy of the process. These automated systems can help in eliminating the delay in the therapy processing solutions when done by manual labor. It even reduces the requirement of a cleanroom space that is costlier to set as well as operate. With the help of automated and closed-cell therapy processing systems, multiple batches can be processed at once.
Request Sample:- Automated and Closed Cell Therapy Processing Systems Market
Market Dynamics
Drivers:
Regenerative medicines help in the repair and replacing of diseased as well as damaged cells. There are multiple processes that are used in the development of regenerative medicines. Tissue engineering is a crucial process for the development of regenerative medicine. The organs which are either damaged or are suffering from some disease can be easily replaced with the help of regenerative medicine. The development of regenerative medicine is expected to propel the demand for automated and closed-cell therapy processing systems.
The cell therapy processing technologies require the use of automated systems in order to speed up the process and eliminate any delay which is usually associated with the manual processes. The automated and closed-cell therapy processing systems are gaining popularity in cell therapy applications owing to the integration of several processes and reduced complexity. With the help of an automation system, the probability of cross-contamination is almost reduced to zero.
Restraints:
The installation cost of automated and closed-cell therapy processing systems is expensive, and thus it cannot be afforded by many medium and small-scale consumers. There are too many features in the closed-cell therapy processing systems, which makes it costlier. Further, the maintenance cost adds up to the total cost.
Opportunities:
The increasing incidence of chronic diseases has led to an increase in the number of clinical trials for various medicines. The rising number of demands of clinical trials has further provided lucrative opportunities for the market. Recently, the use of automated and closed-cell therapy processing systems has been gaining popularity in pre-commercial as well as commercial clinical trials. The rising number of clinical trials requires efficient call handling abilities while simultaneously reducing the probability of any error.
Challenges:
The automated and closed-cell therapy processing systems require the passing of stringent regulations in order to be launched in the market. This system helps in the processing of cells, which can be further used in the development of regenerative therapies. Thus, the approval of closed-cell therapy processing systems requires the passing of several stages in order to be proved safe for the required applications.
Segmentation Analysis
The global automated and closed-cell therapy processing systems market has been segmented based on type, workflow, scale, end-users, and regions.
By Type
The type segment includes stem cells and non-stem cells. The non-stem cell segment led the automated and closed-cell therapy processing systems market with a market share of around 63.25% in 2021. This segment's growth is mainly attributed to the fact that they are mainly being preferred in cell therapy processing due to the rising number of product launches. There are various research projects centered on non-stem cells, and thus the demand for automated systems is increasing for non-stem cell types.
By Workflow
The workflow segment includes separation, expansion, apheresis, fill-finish, cryopreservation, and others. The expansion segment led the automated and closed-cell therapy processing systems market with a market share of around 29.32% in 2021. The expansion application is used for different cellular experiments as it is helpful in the research of regenerative medicines. Expansion processes can be centralized using automated and closed-cell therapy processing systems.
By Scale
The scale segment includes pre-commercial and commercial. The pre-commercial segment led the automated and closed-cell therapy processing systems market with a market share of around 74.92% in 2021. Pre-commercial activities include all those processes that are done before launching the product in the market. Thus, the majority of the companies are installing such software in order to gain efficacy in pre-commercial activities. Pre-commercial activities should test the efficacy of the end product in order to be proved successful for the administration of consumers. Therefore, the use of such systems helps in determining the success of the medicine.
By End-user
The end-user segment includes hospitals, diagnostics centers, research laboratories, and others. The research laboratories segment led the automated and closed-cell therapy processing systems market with a market share of around 46.21% in 2021. The research laboratories are involved in the manufacturing of various regenerative medicines and the use of automated and closed-cell processing systems. These systems help in providing faster results and also process a greater number of batches at once.
By Regional Analysis
The regions analyzed for the automated and closed-cell therapy processing system market include North America, Europe, South America, Asia Pacific, and the Middle East, and Africa. North America region dominated the automated and closed-cell therapy processing market and held the 47.15% share of the market revenue in 2021.
Key Industry Players Analysis
To increase their market position in the global automated and closed-cell therapy processing system business, top companies are focusing on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, and partnerships, joint ventures, etc.
Latest Development
Scope of the Report
Global Automated and Closed Cell Therapy Processing Systems Market by Type:
Global Automated and Closed Cell Therapy Processing Systems Market by Workflow:
Global Automated and Closed Cell Therapy Processing Systems Market by Scale:
Global Automated and Closed Cell Therapy Processing Systems Market by End-user:
Global Automated and Closed Cell Therapy Processing Systems Market by Region:
Global automated and closed-cell therapy processing system market is expected to reach USD 5431.06 million by 2028, at a CAGR of 25.18% from 2022 to 2028.
The regions analyzed for the automated and closed-cell therapy processing system market include North America, Europe, South America, Asia Pacific, and the Middle East, and Africa.
The global automated and closed-cell therapy processing system market has been segmented based on type, workflow, scale, end-user, and regions
Rising demand for low maintenance, highly efficient, and versatile automated cell therapy processing system in the molecular biology application, is primarily driving the growth of the automated and closed-cell therapy processing system market.
Leading market players active in the global automated and closed-cell therapy processing system market are Cellares Inc., Lonza, Cytiva, Terumo Corporation, Thermo Fisher Scientific Inc., BioSpherix Inc., MiltenyiBiotec, Fresenius Kabi, Sartorius AG, ThermoGenesis Holdings Inc. among others.
Manufacturers in the automated and closed-cell therapy processing system market are using advanced production technologies to incorporate better results, installation, and performance of the whole process. In addition, the rising number of investments will contribute to the demand for automated and closed-cell therapy processing systems.
The pandemic has significantly affected several industries and has caused a worldwide economic slowdown. In order to stop the spread of the virus, the development of vaccines was the need of the hour. The automated and closed-cell therapy processing systems have risen in recent times, owing to the requirement for the preparation of vaccines. The research and diagnostics laboratories are deploying huge investments in automated systems, thus, creating demand for the automated and closed-cell therapy processing system.
Based on the sales revenue, product offering, and regional presence, the companies are selected.
Political- The automated and closed-cell therapy processing systems require the passing of stringent regulations in order to be launched in the market. This system helps in the processing of cells, which can be further used in the development of regenerative therapies. Thus, the approval of closed-cell therapy processing systems requires the passing of several stages in order to be proved safe for the required applications.
Economic- The increasing incidence of chronic diseases has led to an increase in the number of clinical trials for various medicines. The rising number of demands of clinical trials has further provided lucrative opportunities for the market. Recently, the use of automated and closed-cell therapy processing systems has been gaining popularity in pre-commercial as well as commercial clinical trials. The rising number of clinical trials requires efficient call handling abilities while simultaneously reducing the probability of any error. The installation cost of automated and closed-cell therapy processing systems is expensive, and thus it cannot be afforded by many medium and small-scale consumers. There are too many features in the closed-cell therapy processing systems, which makes it costlier. Further, the maintenance cost adds up to the total cost.
Social- The Asia-Pacific region is likely to register the highest growth during the Projection period due to the rising demand for cell processing due to the increasing number of investments. Moreover, China and Japan are some of the key countries for the automated and closed-cell therapy processing systems market in the Asia-Pacific region. Further, the rising healthcare spending is fueling up the market growth.
Technological- Regenerative medicines help in the repair and replacing of diseased as well as damaged cells. There are multiple processes that are used in the development of regenerative medicines. Tissue engineering is a crucial process for the development of regenerative medicine. The organs which are either damaged or are suffering from some disease can be easily replaced with the help of regenerative medicine. The development of regenerative medicine is expected to propel the demand for automated and closed-cell therapy processing systems.
Environmental- Because of the increasing pollution and changing lifestyle several new diseases are taking place. Many of these diseases are deadly and can take the life of humans. In order to fight these diseases several treatments have been developed which helps in treating these diseases. Government is also taking up stringent actions to fight the pollution and keep the environment clean and green.
Legal- Lonza announced the acquisition of a significant stake in Octane Biotech. Lonza had planned to acquire complete ownership in the company with the objective of developing automated technology for the requirement of scalable autologous. However, Octane Biotech had planned to maintain its exclusivity for the indication of orthopedic clinical in the Cocoon system.
List of Table
List of Figures